Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the future of CAR T-cells and bispecific antibodies to treat myeloma. The current data is from first-generation CAR T-cells and bispecific antibodies which are used alone to treat highly refractory resistant patients. In the future, combining CAR T-cells with immunomodulatory drugs will hopefully increase the longevity of CAR T-cells and improve progression-free survival. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.

свернуть